Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564015 | 0.79 | KDM4E (0.35) | — | |
| SCHEMBL20564353 | 0.79 | HPGD (0.41) | — | |
| SCHEMBL7774207 | 0.74 | HPGD (0.37) | — | |
| SCHEMBL28523051 | 0.71 | PTPN1 (0.31) | — | |
| SCHEMBL4629349 | 0.71 | KCNA3 (0.37) | — | |
| SCHEMBL28403962 | 0.70 | HPGD (0.42) | — | |
| SCHEMBL20577100 | 0.69 | MAOB (0.53) | — | |
| SCHEMBL6258287 | 0.68 | THRA (0.36) | — | |
| SCHEMBL158136 | 0.67 | — | — | |
| SCHEMBL1068522 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074829-B2 | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-6559181-B1 | A method to treat endometrial carcinoma, prostate cancer, or prostate hyperplasia comprising administering to a patient in need of such treatment an effective dose of a 3,4-Diphenyl-bicyclo(4.3.0)nonyl compound of formula I | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-06 | — | — | US | disclosed |
| EP-1086077-A1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | Schering Aktiengesellschaft (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6166075-A | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| WO-1999064393-A1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | CYP19A1, NR5A1, HSD17B11 | KLK1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.